TScan Therapeutics, Inc.

Stage 4 · Declining · week 20

As of Oct 22, 2026, TScan Therapeutics is in Stage 4, the downtrend phase, now in week 20 (since Jun 4, 2026). It closed at $0.22, 90.6% below its 52-week high and below its 200-day average, which is falling.

$0.22

-1.37% today

$14.7M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is TCRX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 38w

S4 43w

S1 16w

S4 20w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 5w → S1 2w → S2 38w → S3 7w → S4 43w → S1 16w → S2 4w → S3 3w → S4 13w → S1 4w → S4 3w → S1 6w → S4 20w current

Total tracked: 166 weeks across 13 stage runs.

TCRX among Biotechnology509th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…509	TCRXTScan Therapeutics, Inc.	Stage 4 · wk 20	7	−40.7%

vs 52W High

-90.6%

$0.21 lo$2.31 hi

90.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 20

1w13w26w

Week 20, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-75.5%

200 DMA: $0.88 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.36x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-40.7%

-72.8%

-82.0%

YTD

-78.8%

-90.8%

Scan Membership

Breakout Watch

Latest: 2023-10-09

2 appearances in last 60 days. First seen: 2023-05-17.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 20 · Vol 0.36x

2026-10-21S4

Wk 20 · Vol 0.80x

2026-10-20S4

Wk 20 · Vol 0.68x

2026-10-19S4

Wk 19 · Vol 0.45x

2026-10-16S4

Wk 19 · Vol 0.70x

2026-10-15S4

Wk 19 · Vol 1.09x

2026-10-14S4

Wk 19 · Vol 0.67x

2026-10-13S4

Wk 19 · Vol 0.57x

2026-10-12S4

Wk 18 · Vol 0.60x

2026-10-09S4

Wk 18 · Vol 1.09x

2026-10-08S4

Wk 18 · Vol 1.97x

2026-10-07S4

Wk 18 · Vol 0.69x

Moving averages & range

50 DMA

$0.43

200 DMA

$0.88

52W High

$2.31

52W Low

$0.21

5D Low

$0.21

Resistance levels (recent highs)

20d High

$0.34

60d High

$0.83

120d High

$1.26

250d High

$2.31

Next resistance

+57.4%

to 20d High

ROE

-95.8%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.2

TScan Therapeutics: quick answers

What stage is TScan Therapeutics in?

As of Oct 22, 2026, TScan Therapeutics (TCRX) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 4, 2026 and is in week 20. What the four stages mean

Is TScan Therapeutics in an uptrend?

No. TScan Therapeutics is in a Stage 4 downtrend. It trades 75.5% below its 200-day average, which is falling.

How far is TScan Therapeutics from its 52-week high?

TScan Therapeutics closed at $0.22 on Oct 22, 2026, 90.6% below its 52-week high of $2.31. Its 52-week low is $0.21.

How has TScan Therapeutics performed over the past year?

As of Oct 22, 2026, TScan Therapeutics is down 90.8% over the past year and down 78.8% so far in 2026.

Which sector and industry is TScan Therapeutics in?

TScan Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.